News
ICViewExpert PerspectivesMedical World NewsPathogen PlaybookVideosWebinars
Conference CoverageConference ListingAPIC Chapters
Infection Control TodaySupplements And Featured Publications
CME/CEEditorial Advisory BoardJob BoardPartnersSponsoredWhitepapers
Subscribe
Educator of the Year Official Rules2024 Educator of the Year Winner2023 Educator of the Year WinnerEducator of the Year
Advanced TechnologyAdvanced TechnologyAdvanced Technology
Bug of the Month
COVID-19
Environmental ServicesEnvironmental Services
HAIs
Hand Hygiene
IC Trends
Long-Term CareLong-Term Care
Operating Room
Personal Protective EquipmentPersonal Protective Equipment
Policy
PreventionPreventionPreventionPrevention
Sterile ProcessingSterile Processing
Surface Disinfection
Vascular Access
Spotlight -
  • IC Trends
  • Bug of the Month
  • Featured Articles
  • Featured Columns
  • Pathogen Playbook
Advanced TechnologyAdvanced TechnologyAdvanced Technology
Bug of the Month
COVID-19
Environmental ServicesEnvironmental Services
HAIs
Hand Hygiene
IC Trends
Long-Term CareLong-Term Care
Operating Room
Personal Protective EquipmentPersonal Protective Equipment
Policy
PreventionPreventionPreventionPrevention
Sterile ProcessingSterile Processing
Surface Disinfection
Vascular Access
    • News
    • Subscribe
Advertisement

Study Shows Restored Immunity for Cancer-Related Fungal Infections

July 8, 2014
Article

A study at the University of Texas MD Anderson Cancer Center used the Sleeping Beauty gene transfer system to modify T cells in hopes of fighting major life-threatening infections caused by invasive Aspergillus fungus. Results of the study appear in today’s issue of the Proceedings of the National Academy of Sciences (PNAS).

This type of gene therapy is already being used to recognize antigens associated with tumors. Clinical trials at MD Anderson were the first to use Sleeping Beauty to customize immune system T cells to attack specific types of leukemia and lymphoma.

The Aspergillus study, led by Laurence Cooper, MD, PhD, professor in pediatrics at MD Anderson, shows that it may also be effective for combatting fungal infections that can be deadly for immunosuppressed patients such as those receiving hematopoietic stem cell transplants. The transplants are used to treat cancers of the blood or bone marrow such as leukemia, lymphoma, and multiple myeloma.

Cooper’s study, which included collaboration with Dimitrios Kontoyiannis, MD, ScD, professor in the Department of Infectious Diseases, employed a novel method for inhibiting growth of fungus. The Sleeping Beauty system, developed at the University of Minnesota, offered a fresh approach to genetically modifying T cells for human use which is being piloted at MD Anderson for immunotherapy.

The team harnessed Sleeping Beauty to engineer human T cells to express receptors known as chimeric antigen receptors (CARs) which redirected the killing machinery of the T cells. T cells displaying CAR targeted sugar molecules in the Aspergillus cell walls, killing the fungus.

“Mortality associated with invasive Aspergillus remains unacceptably high, especially in hematopoietic stem cell transplant recipients,” says Kontoyiannis. “While antifungal therapies are available, the patient’s own weakened immune system and emerging resistance to antifungals compromise the drugs’ effectiveness. There is a dire need for effective immune enhancements strategies for the treatment of opportunistic fungal infections in patients with profound and persistent immune defects.”

Cooper says that new approaches for treating invasive Aspergillus are urgently needed. Since use of CARs has resulted in successful treatment of patients with B-cell malignancies, his team sought to determine if a CAR could be developed to redirect T-cell specificity to fungus.

The Sleeping Beauty gene transfer system earned its name by its ability to “awaken” certain DNA sequences known as transposon. Researchers find transposon useful as a means to alter DNA inside human cells. Sleeping Beauty uses transposon in a “cut and paste” approach to relocating genetic material.

“We demonstrated a new approach for Aspergillus immunotherapy based on redirecting T-cell specificity through a CAR that recognizes carbohydrate antigen on the fungal cell wall,” says Cooper. “The T cells expressing the CAR can be manipulated in a manner suitable for human application, enabling this immunology to be translated into immunotherapy.”

The approach has implications for genetically modifying T cells to target carbohydrate, and thus broadening their application in the investigational treatment of pathogens as well as malignancies.

Co-authors for the PNAS paper included Dimitrios Kontoyiannis, MD, professor in the Department of Infectious Diseases, and Richard Champlin, MD, PhD, chair of the Department of Stem Cell Transplantation.

The study was funded by the Cancer Center Core Grant (CA16672), the National Institutes of Health (RO1 CA124782, CA 120956, CA141303, R33 CA116127, and P01 CA148600), the Burroughs Wellcome Fund, the Cancer Prevention Research Institute of Texas, the Chronic Lymphocytic Leukemia Global Research Foundation, the Defense Advanced Research Projects Agency, the U.S. Department of Defense, the estate of Noelan L. Bibler, the Gillson Longenbaugh Foundation, the Harry T. Mangurian, Jr. Fund for Leukemia Immunotherapy, the Institute of Personalized Cancer Therapy, the Leukemia and Lymphoma Society, the Lymphoma Research Foundation, the MD Anderson Cancer Center’s Sister Institution Network Fund, the Miller Foundation, Herb Simons, Mr. and Mrs. Joe H. Scales, Thomas Scott, the National Foundation for Cancer Research, the Pediatric Cancer Research Foundation, and the William Lawrence and Blanche Hughes Children’s Foundation.

Source: University of Texas M. D. Anderson Cancer Center 

Recent Videos
Pathogen Playbook Presenter: Sharon Ward-Fore, BS, MS, MT(ASCP), CIC, FAPIC
Mark Wiencek, PhD
Rebecca Crapanzano-Sigafoos, DrPH, CIC, AL-CIP, FAPIC
The CDC’s updated hospital respiratory reporting requirement has added new layers of responsibility for infection preventionists. Karen Jones, MPH, RN, CIC, FAPIC, clinical program manager at Wolters Kluwer, breaks down what it means and how IPs can adapt.
Studying for the CIC using a digital tablet and computer (Adobe Stock 335828989 by NIKCOA)
Infection Control Today's Conversations with the HSPA President, Arlene Bush, CRCST, CER, CIS, SME, DSMD, CRMST
Infection Control Today's Conversations with the HSPA President, Arlene Bush, CRCST, CER, CIS, SME, DSMD, CRMST
Cheron Rojo, BS, FCS, CHL,  CER, CFER, CRCST
Matthias Tschoerner, Dr Sc
Standardizing Cleaning and Disinfection
Related Content

The Clean Bite

Personal Protective Equipment (PPE) for Dental Professionals: A Layered Defense

Sherrie Busby, EDDA, CDSO, CDIPC
July 1st 2025
Article

Dental infection control expert Sherrie Busby tackles PPE missteps, from chin-bra masks to cropped lab coats, reminding dental teams that proper protection is crucial, not optional.


Rebecca Battjes, MPH, CIC, FAPIC; Vidya Nankoosingh, MLT, CIC; and Peter Teska, MBA

Beyond the Surface: Rethinking Environmental Hygiene Validation at Exchange25

Tori Whitacre Martonicz
June 30th 2025
Article

Environmental hygiene is about more than just shiny surfaces. At Exchange25, infection prevention experts urged the field to look deeper, rethink blame, and validate cleaning efforts across the entire care environment, not just EVS tasks.


ACIP decides on vaccinations   (Adobe Stock 606491608 by N Lawrenson/peopleimages.com)

New ACIP Panel Backs Seasonal Flu, RSV Vaccinations, but Divisions Emerge Over Thimerosal and Infant Dosing

Richard Payerchin
June 27th 2025
Article

In its first major session under newly appointed leadership, the revamped Advisory Committee on Immunization Practices (ACIP) voted to support flu and RSV vaccinations for the 2025–2026 season, but internal debate over vaccine preservatives, access equity, and risk assessment highlighted the ideological and scientific tensions now shaping federal vaccine policy.


US Department of Health and Human Services

A Controversial Reboot: New Vaccine Panel Faces Scrutiny, Support, and Sharp Divides

Richard Payerchin
June 26th 2025
Article

As the newly appointed Advisory Committee on Immunization Practices (ACIP) met for the first time under sweeping changes by HHS Secretary Robert F. Kennedy Jr, the national spotlight turned to the panel’s legitimacy, vaccine guidance, and whether science or ideology would steer public health policy in a polarized era.


Jill Holdsworth, CIC, FAPIC, NREMT, CRCST, CHL; and Katie Belski, BSHCA, CRCST, CHL, CIS, CER, At HSPA25

Getting Down and Dirty With PPE: Presentations at HSPA by Jill Holdsworth and Katie Belski

Betsy Donahue, MA
June 26th 2025
Article

In the heart of the hospital, decontamination technicians tackle one of health care’s dirtiest—and most vital—jobs. At HSPA 2025, 6 packed workshops led by experts Jill Holdsworth and Katie Belski spotlighted the crucial, often-overlooked art of PPE removal. The message was clear: proper doffing saves lives, starting with your own.


Infection Control Today's Hot Topics in IPC

Hot Topics for IPC for June 25, 2025: The Future of ACIP, Measles, and More

Saskia v. Popescu, PhD, MPH, MA, CIC, FAPIC
June 25th 2025
Article

This Hot Topics for IPC covers the latest on ACIP, vaccines, and a study on contact precautions for MRSA.

Related Content

The Clean Bite

Personal Protective Equipment (PPE) for Dental Professionals: A Layered Defense

Sherrie Busby, EDDA, CDSO, CDIPC
July 1st 2025
Article

Dental infection control expert Sherrie Busby tackles PPE missteps, from chin-bra masks to cropped lab coats, reminding dental teams that proper protection is crucial, not optional.


Rebecca Battjes, MPH, CIC, FAPIC; Vidya Nankoosingh, MLT, CIC; and Peter Teska, MBA

Beyond the Surface: Rethinking Environmental Hygiene Validation at Exchange25

Tori Whitacre Martonicz
June 30th 2025
Article

Environmental hygiene is about more than just shiny surfaces. At Exchange25, infection prevention experts urged the field to look deeper, rethink blame, and validate cleaning efforts across the entire care environment, not just EVS tasks.


ACIP decides on vaccinations   (Adobe Stock 606491608 by N Lawrenson/peopleimages.com)

New ACIP Panel Backs Seasonal Flu, RSV Vaccinations, but Divisions Emerge Over Thimerosal and Infant Dosing

Richard Payerchin
June 27th 2025
Article

In its first major session under newly appointed leadership, the revamped Advisory Committee on Immunization Practices (ACIP) voted to support flu and RSV vaccinations for the 2025–2026 season, but internal debate over vaccine preservatives, access equity, and risk assessment highlighted the ideological and scientific tensions now shaping federal vaccine policy.


US Department of Health and Human Services

A Controversial Reboot: New Vaccine Panel Faces Scrutiny, Support, and Sharp Divides

Richard Payerchin
June 26th 2025
Article

As the newly appointed Advisory Committee on Immunization Practices (ACIP) met for the first time under sweeping changes by HHS Secretary Robert F. Kennedy Jr, the national spotlight turned to the panel’s legitimacy, vaccine guidance, and whether science or ideology would steer public health policy in a polarized era.


Jill Holdsworth, CIC, FAPIC, NREMT, CRCST, CHL; and Katie Belski, BSHCA, CRCST, CHL, CIS, CER, At HSPA25

Getting Down and Dirty With PPE: Presentations at HSPA by Jill Holdsworth and Katie Belski

Betsy Donahue, MA
June 26th 2025
Article

In the heart of the hospital, decontamination technicians tackle one of health care’s dirtiest—and most vital—jobs. At HSPA 2025, 6 packed workshops led by experts Jill Holdsworth and Katie Belski spotlighted the crucial, often-overlooked art of PPE removal. The message was clear: proper doffing saves lives, starting with your own.


Infection Control Today's Hot Topics in IPC

Hot Topics for IPC for June 25, 2025: The Future of ACIP, Measles, and More

Saskia v. Popescu, PhD, MPH, MA, CIC, FAPIC
June 25th 2025
Article

This Hot Topics for IPC covers the latest on ACIP, vaccines, and a study on contact precautions for MRSA.

Advertise
About Us
Editorial Board
Contact Us
Job Board
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.
Home
About Us
News